EyePoint Reports Topline P-III (LUCIA) Trial Results of Duravyu (Vorolanib Intravitreal Insert) for Wet AMD

Shots: EyePoint reported that its second pivotal P-III (LUCIA) trial (n=475) evaluating Duravyu (vorolanib intravitreal insert; 2.7mg Q24W) vs on-label aflibercept (2mg Q8W) after 3 monthly loading doses in pts with wet AMD did not meet its 1EP of statistical non-inferiority in mean change in BCVA at blended Wks. 52 & 56, despite demonstrating visual improvement Key 2EPs were met, incl. a 38% reduction in treatment burden (nominal p<0.0001), with 52% of eyes supplement-free & 71% receiving 0 or 1 supplement up to Wk. 56, strong anatomic control & a continued favorable safety profile with redosing; the identical P-III (LUGANO; n=432) trial also did not meet its 1EP in its full dataset, while showing a 42% reduction in treatment burden EyePoint will complete additional analyses of the LUCIA & pooled P-III datasets to assess next steps for Duravyu in wet AMD, while its DME program remains on track with topline data from the P-III (COMO & CAPRI) trials expected in Q4’27; Duravyu combines the TKI vorolanib with EyePoint’s bioerodible Durasert E sustained-delivery technology Ref: Globenewswire  |   Image: EyePoint  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post EyePoint Reports Topline P-III (LUCIA) Trial Results of Duravyu (Vorolanib Intravitreal Insert) for Wet AMD appeared first on PharmaShots.